receiving ADT. We collected their clinical and demographic data, and whether BT was administered. Because our study period preceded the approval of novel agents for mCP and the shift to upfront chemotherapy, we defined castrate resistance as the initiation of chemotherapy. Statistical analysis was performed using SAS v9.3 (Cary, NC).
receiving ADT. We collected their clinical and demographic data, and whether BT was administered. Because our study period preceded the approval of novel agents for mCP and the shift to upfront chemotherapy, we defined castrate resistance as the initiation of chemotherapy. Statistical analysis was performed using SAS v9.3 (Cary, NC).
RESULTS: A total of 2563 men were treated with ADT for mCP, and BT was administered to 431 (16.8%) . Utilization of BT increased significantly during the study period, from 5.9% in 2004 to 35.2% in 2011 (p<0.01) . On multivariate analysis, men had increased odds of receiving BT if year of diagnosis was later than 2008 or an oncologist was involved in their care, and decreased odds of BT if receiving care in a less urban area (p<0.05, Table 1 ). Among the subset of men with mCRCP (433, 16.9%), BT was administered to 136 (31.4%). On multivariate analysis, age 80-85 and diagnosis year later than 2010 were associated with increased odds of BT (OR 2.57 and 1.57, respectively; p¼0.01). Adverse events related to BT were rare, with osteonecrosis of the jaw occurring in 7 (1.6%) and hypocalcemia in 34 (8.0%).
CONCLUSIONS: Utilization of BT among men with mCP is increasing, though the overall usage of these medications remains low. Among men with mCRCP, only 31.4% received bone health treatments in accordance with NCCN guidelines. As novel anti-androgens expand the role of urologists in management of mCRCP, careful consideration of appropriate management of bone health must not be overlooked.
Source of Funding: Northshore University Health System

PD24-07 EFFICACY AND SAFETY OF RADIUM-223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL
Laurence Klotz*, Toronto, Canada; Christopher Sweeney, Boston, MA; Adam Dicker, philadelphia, PA; Nicholas Vogelzang, Las Vegas, NV; Michael Morris, New York, NY; Frank Verholen, Volker Wagner, Basel, Switzerland; Cindy Lu, Whippany, NJ; Christopher Parker, Sutton, United Kingdom; Oliver Sartor, New Orleans, AL INTRODUCTION AND OBJECTIVES: Radium-223 (Ra-223), a targeted alpha therapy, significantly improved overall survival (OS) versus (vs) placebo (pbo) for patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in ALSYMPCA trial (HR ¼ 0.70; 95% CI, 0.58-0.83; P < 0.001) and was well tolerated. We hypothesized that outcome with Ra-223 in ALSYMPCA is similar whether or not pts underwent radical local therapy (RLT) for prostate cancer (PC) at initial diagnosis.
METHODS: ALSYMPCA eligible pts had progressive mCRPC with 2 bone lesions and no known visceral metastases. Pts were randomized 2:1 to 6 injections of Ra-223 (55 kBq/kg IV; q4 wk) plus best standard of care (BSoC) or matching pbo plus BSoC. Exploratory subgroup analyses were performed to evaluate outcome of Ra-223 vs pbo by RLT (defined as radical prostatectomy or radiation to prostate) and according to metastatic status at initial diagnosis.
RESULTS: 921 pts were treated (Ra-223, n ¼ 614; pbo, n ¼ 307). 392 (43%) received RLT at initial diagnosis and 529 (57%) did not. Median OS was longer with Ra-223 vs pbo regardless of whether pts received RLT or not [(with RLT: 15.3 (table) . Therapies received prior to ALSYMPCA trial initiation were mainly RLT (mostly M0), bilateral orchiectomy, LHRH agonist, anti-androgens, chemotherapy and external radiotherapy to bone. These prior therapies were generally balanced between Ra-223 and pbo groups. Safety and pts demographics for the subgroups will be presented.
CONCLUSIONS: Compared with pbo, Ra-223 improved OS in mCRPC patients. A subgroup analysis indicates that OS is consistent regardless of whether pts had received RLT or not at initial diagnosis. Similarly, OS is consistent regardless of metastatic status at initial diagnosis.
Source of Funding: Bayer Pharmaceuticals
PD24-08 TESTOSTERONE RESPONDERS TO CONTINUOUS ANDROGEN DEPRIVATION THERAPY EXHIBIT CONSIDERABLE VARIATION IN TESTOSTERONE LEVELS ON FOLLOW UP
Rashid Sayyid*, Abdallah Sayyid, Nathan Perlis, Hanan Goldberg, Karen Chadwick, Antonio Finelli, Alexandre Zlotta, Robert Hamilton, Girish Kulkarni, Neil Fleshner, Toronto, Canada INTRODUCTION AND OBJECTIVES: Lower nadir serum testosterone (T) levels in prostate cancer (PCa) patients receiving continuous androgen deprivation therapy (ADT) has been shown to be associated with improved cancer-specific survival and time to hormone resistance. In light of recommendations for measuring T level and acting on its result, we set out to determine whether variations in serum T levels exist among patients with ideal testosterone castration response.
METHODS: Serum T levels were obtained retrospectively from a random sample of 551 PCa patients receiving continuous ADT between 2007 and 2016, accounting for a total of 4,815 measurements. All patients achieved T levels 0.7 ng/mL during course of treatment (i.e.
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